,
Soler Artigas, María http://orcid.org/0000-0002-3213-1107
Sánchez-Mora, Cristina http://orcid.org/0000-0003-4211-1107
Rovira, Paula
Richarte, Vanesa
Garcia-Martínez, Iris
Pagerols, Mireia
Demontis, Ditte http://orcid.org/0000-0001-9124-2766
Stringer, Sven
Vink, Jacqueline M. http://orcid.org/0000-0003-3910-3528
Børglum, Anders D.
Neale, Benjamin M. http://orcid.org/0000-0003-1513-6077
Franke, Barbara http://orcid.org/0000-0003-4375-6572
Faraone, Stephen V. http://orcid.org/0000-0002-9217-3982
Casas, Miguel
Ramos-Quiroga, Josep Antoni
Ribasés, Marta
Article History
Received: 1 March 2018
Revised: 2 November 2018
Accepted: 10 December 2018
First Online: 4 January 2019
Change Date: 25 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41380-021-01049-6
Compliance with ethical standards
:
: M.C. has received travel grants and research support from Eli Lilly and Co., Janssen-Cilag, Shire, and Laboratorios Rubió. He has been on the advisory board and served as a consultant for Eli Lilly and Co., Janssen-Cilag, Shire, and Laboratorios Rubió. In the past year, S.V.F. received income, potential income, travel expenses continuing education support and/or research support from Otsuka, Arbor, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Ironshore, Sunovion, and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. B.F. has received educational speaking fees from Shire and Medice. J.A.R.Q. has served on the speakers’ bureau and acted as a consultant for Eli Lilly and Co., Janssen-Cilag, Novartis, Lundbeck, Shire, Ferrer, and Laboratorios Rubió. He has received travel awards from Eli Lilly and Co., Janssen-Cilag, and Shire for participating in psychiatric meetings. The ADHD Program chaired by J.A.R.Q. has received unrestricted educational and research support from Eli Lilly and Co., Janssen-Cilag, Shire, Rovi, and Laboratorios Rubió in the past two years. B.N. is a member of the scientific advisory board at Deep Genomics and RBNC Therapeutics and a consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen. The remaining authors declare that they have no conflict of interest.